Membranoproliferative glomerulonephritis secondary prevention: Difference between revisions
Aditya Ganti (talk | contribs) No edit summary |
Aditya Ganti (talk | contribs) |
||
Line 6: | Line 6: | ||
== Secondary prevention == | == Secondary prevention == | ||
Effective measures for the secondary prevention of MPGN include medications to reduce the progression of ESRD which include:<ref>{{Cite journal|last=Kambiz Zandi-Nejad, and Barry M. Brenner|first=|date=|title=Primary and secondary prevention of chronic kidney disease|url=|journal=Journal of hypertension|volume=23|pages=10|via=}}</ref> | |||
* Angiotensin-converting enzyme (ACE) inhibitors | * Angiotensin-converting enzyme (ACE) inhibitors | ||
* Angiotensin-receptor blockers | * Angiotensin-receptor blockers |
Revision as of 20:27, 6 August 2018
Membranoproliferative glomerulonephritis Microchapters |
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Membranoproliferative glomerulonephritis secondary prevention On the Web |
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis secondary prevention |
FDA on Membranoproliferative glomerulonephritis secondary prevention |
CDC on Membranoproliferative glomerulonephritis secondary prevention |
Membranoproliferative glomerulonephritis secondary prevention in the news |
Blogs on Membranoproliferative glomerulonephritis secondary prevention |
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
Risk calculators and risk factors for Membranoproliferative glomerulonephritis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:
Overview
Secondary prevention of strategy is a method to reduce the complication of disease, and one of the most important complication of MPGN is end-stage renal disease (ESRD).
Secondary prevention
Effective measures for the secondary prevention of MPGN include medications to reduce the progression of ESRD which include:[1]
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin-receptor blockers
- Combined ACE inhibition and angiotensin receptor antagonism
- Dietary protein restriction
References
- ↑ Kambiz Zandi-Nejad, and Barry M. Brenner. "Primary and secondary prevention of chronic kidney disease". Journal of hypertension. 23: 10.